Transport Theory for HIV Diffusion through In Vivo Distributions of Topical Microbicide Gels  by Lai, Bonnie E. et al.
Biophysical Journal Volume 97 November 2009 2379–2387 2379Transport Theory for HIV Diffusion through In Vivo Distributions of Topical
Microbicide Gels
Bonnie E. Lai,† Marcus H. Henderson,† Jennifer J. Peters,† David K. Walmer,‡ and David F. Katz†‡*
†Department of Biomedical Engineering and ‡Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina
ABSTRACT Topical microbicide products are being developed for the prevention of sexually transmitted infections. These
include vaginally-applied gels that deliver anti-HIV molecules. Gels may also provide partial barriers that slow virion diffusion
from semen to vulnerable epithelium, increasing the time during which anti-HIV molecules can act. To explore the barrier function
of microbicide gels, we developed a deterministic mathematical model for HIV diffusion through realistic gel distributions. We
applied the model to experimental data for in vivo coating distributions of two vaginal gels in women. Time required for a threshold
number of virions to reach the tissue surface was used as a metric for comparing different scenarios. Results delineated how time
to threshold increased with increasing gel layer thickness and with decreasing diffusion coefﬁcient. We note that for gel layers
with average thickness >~100 mm, the fractional area coated, rather than the gel layer thickness, was the primary determinant of
time to threshold. For gel layers <~100 mm, time to threshold was brief, regardless of fractional area coated. Application of the
model to vaginal coating data showed little difference in time to threshold between the two gels tested. However, the protocol
after gel application (i.e., with or without simulated coitus) had a much more signiﬁcant effect. This study suggests that gel distri-
bution in layers of thickness >100 mm and fractional area coated >0.8 is critical in determining the ability of the gel to serve as
a barrier to HIV diffusion.INTRODUCTION
Mathematical models of pharmacokinetics and pharmacody-
namics have provided insights for the development of antire-
troviral therapy (1,2) and informed our understanding of
acquired immune deficiency syndrome (AIDS) pathology
and the immune system (3–5). However, there have been
few attempts to create analogous mathematical models for
topical microbicides for human immunodeficiency virus
(HIV) prevention.
Microbicides are agents applied topically to prevent trans-
mission of sexually transmitted infections, including HIV
(6–8). Microbicide development has been motivated by the
lack of a prophylactic vaccine for HIV/AIDS (9) and the
lack of female-controlled methods of HIV prevention (10).
First-generation microbicide candidates acted via nonspe-
cific mechanisms of action. These included vaginal defense
enhancers, surfactants, and entry and fusion inhibitors. To
date, clinical trials of first-generation products have not
demonstrated efficacy for HIV prevention (11–14). Subse-
quent microbicide development has shifted toward active
pharmaceutical agents (APIs) with HIV-specific mechanisms
of action (15).
Mathematical models have the potential to contribute to
microbicide design and evaluation. To date, two approaches
have been employed to mathematically describe the func-
tioning of microbicides: stochastic models of infectivity
and deterministic transport models. Tuckwell et al. devel-
oped a stochastic approach (16) derived from clinical data
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An advantage of the stochastic approach is that it can incor-
porate data for rates of infection provided by epidemiological
studies and clinical trials. Model predictions can provide
insights for clinical trial design. However, one limitation of
stochastic modeling is that it provides limited insight into mi-
crobicide product functioning and biological mechanisms
underlying HIV infection. Parameters that describe microbi-
cide efficacy and likelihood of infection are empirically
derived, and summarize complex underlying phenomena.
An alternative modeling approach, used by our group, is to
develop deterministic models of HIV and microbicide trans-
port and neutralization processes (18,19). These models
consider parameters relevant to the development of topical
microbicide formulations, such as rates of drug delivery,
rates of HIV diffusion, and spatial deployment of drug
delivery vehicles. The advantage of this approach is that
these mathematical models can serve as tools for microbicide
developers, helping them to interpret product characteristics.
However, this approach is hampered by limited experimental
data linking model parameters to clinical outcomes.
Models embodying parameters relevant to drug delivery
can be used in design of microbicide products, e.g., in spec-
ifying drug loading and release rates from the dosage form,
and determining the optimal timing for product application
in relation to exposure to sexually transmitted infection path-
ogens. Dosage forms for microbicides have included semi-
solid gels, intravaginal rings, quick-dissolve films, and
tablets (20,21). Intended methods of use may be coitus-
dependent or coitus-independent. Different mathematical
models are necessary for different microbicide product
scenarios. Microbicide developers may have different goals
doi: 10.1016/j.bpj.2009.08.010
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and the intended method of use. For example, APIs may
focus on neutralizing HIV in fluids of the vaginal lumen
(e.g., HIV-targeted entry inhibitors) or within the vaginal
epithelium (e.g., reverse transcriptase inhibitors). Different
mathematical models are needed to characterize different mi-
crobicide products.
In this study, we used transport theory to describe HIV
virions diffusing from semen through microbicide gel to
vulnerable vaginal epithelial surfaces. The biological context
of our analysis is the time interval after ejaculation during
which HIV virions introduced in semen are deposited in
the lower female reproductive tract. We were interested in
the functioning of microbicide gels as semipermeable bar-
riers to HIV and in how the spatial deployment of gels
in vivo affects this function.
To date, the functional significance of hindering HIV
transport through semisolid microbicide products has not
been comprehensively studied. Barrier methods such as
condoms are known to be an effective means of preventing
HIV transmission (10). Moreover, biological physical
barriers, such as epithelial tissue and mucus, comprise the
first line of an imperfect innate immune defense. However,
it is less clear how barriers created by semisolid microbicide
products could contribute to preventing HIV transmission.
Our previous work suggested that hindrance of virion diffu-
sion is crucial to allowing APIs the time necessary to
neutralize virions in the vaginal lumen before they reach
vulnerable tissue surfaces (18). Furthermore, HIV has a finite
infectious lifetime in vitro and presumably in vivo, thus,
hindering HIV transport rates could reduce the infectious
viral inoculum arriving at vulnerable tissue surfaces. This
might also provide innate host defenses extended time in
which to neutralize the virus. Overall, hindering HIV trans-
port could potentially reduce the inoculum of infectious
virions that reaches tissue surfaces in vivo, which provides
motivation for further studies of the potential barrier effects
of microbicide products.
We use here the time required for a threshold number of
virions to reach the tissue compartment as a metric for
comparing different scenarios. This allowed us to study the
barrier function of gels without limiting ourselves to specific
microbicide APIs. Thus, although this model does not
address neutralization by APIs, it provides a foundation for
future models that will include specific mechanisms of action
by APIs. Results here provide a useful first approximation of
the lower bound of time required for virions to diffuse from
infectious semen, through vaginal gels, to tissue.
In this study, we also considered realistic deployment of
vaginal gels in vivo. Previously, we modeled an idealized
geometry in which vaginal tissue was coated completely
by a layer of constant thickness (18). However, optical
imaging experiments performed by our lab have shown
that vaginal coating by gels in women is not so uniform:
coating thickness varies spatially, and not all tissue is
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an’s posture and activity after gel application, as much as
one-third of the epithelial surface area has been found to
be devoid of detectable coating (22,23). The distribution of
coating thickness likely affects transport and interactions
between HIV virions and APIs and, thus, the prophylactic
functioning of the gel. Algorithms based upon how coating
details affect actual HIV and API transport kinetics would
enhance the biological interpretations of imaging studies.
The goal of this study was to define and understand
parameters salient to the functioning of a semisolid microbi-
cide gel as a barrier to HIV diffusion. We developed a math-
ematical model for HIV diffusion from semen, through real-
istically-deployed microbicide gel, to vaginal epithelial
surfaces where early events of infection occur. Our results
provide insights about the time required for virions to contact
vaginal epithelium, and how that is influenced by viral
mobility in epithelial coating with a gel, as well as details
of that coating.
MATERIALS AND METHODS
Mathematical model of 1-D HIV diffusion through
semen and microbicide gel
Fig. 1 illustrates our model. Microbicides formulated as gels are applied
topically to the vagina. Previous in vivo studies have found that vaginal
gels deploy to partially coat the epithelium, forming layers ~100 mm thick
(23,24). These layers may then be challenged by semen containing infec-
tious HIV. We model HIV-virion transport from semen, through coating
layers (where present), to vaginal tissue as an unsteady one-dimensional
diffusion process in two compartments (semen, gel) (Fig. 2). First, we create
a model of local HIV diffusion from semen to tissue that is partially coated
by a gel layer of constant thickness. Then, we expand the analysis to trans-
port to a partially coated surface with a distribution of coating thicknesses
FIGURE 1 Schematic of female reproductive tract showing how microbi-
cide gel and semen may be deployed after coitus. (Inset) Idealized scenario
for mathematical modeling of a semen layer on top of a microbicide gel
layer.
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variable definitions and parameter values.
Governing equations
The transport equations for HIV diffusion in the semen and gel layers are
vCHIV
vt
¼ DHIV;semen v
2CHIV
vx2
; (1)
vCHIV
vt
¼ DHIV;gel v
2CHIV
vx2
: (2)
The assumption of one-dimensional diffusion is reasonable, because vaginal
coating thickness is generally small compared to the lateral scale over which
it varies.
Boundary conditions
The vagina is treated as a collapsed flat tube (26) with symmetry about x¼ 0
(Fig. 2). The symmetry boundary condition at x ¼ 0 is
FIGURE 2 Schematic of mathematical model of HIV migration from
semen layer, through microbicide gel layer, into tissue compartment.vCHIVð0; tÞ
vx
¼ 0: (3)
At the interface of the semen and gel layers, standard concentration and flux
boundary conditions are represented by
CHIV

hþsemen; t
 ¼ FHIVCHIVhsemen; t; (4)
DHIV;gel
vCHIV

hþsemen; t

vx
¼ DHIV;semen
vCHIV

hsemen; t

vx
: (5)
Here, hsemen
þ and hsemen
 are positions infinitesimally above and below the
semen-gel interface, respectively.
The boundary condition between gel and tissue compartments is not well
understood. Virions likely accumulate on the vaginal epithelial surface
because the squamous epithelial cells form a physical barrier (27). Recent
work by Hope et al. suggests that HIV virions can diffuse through intact
epithelial tissue in vivo, presumably by moving through gaps between cells
(28). Given this current lack of quantitative understanding, we apply a zero-
concentration boundary condition at the gel/tissue interface:
CHIVðhtotal; tÞ ¼ 0: (6)
This condition maximizes flux into the tissue compartment and provides
conservative estimates for times needed to reach threshold levels of infec-
tious virus at the tissue surface.
Initial conditions
At time zero, HIV is introduced at concentration C0 in the semen. The
concentration within the microbicide gel layer is zero:
CHIVðx; 0Þ ¼ C0 for 0%x < hsemen; (7)
CHIVðx; 0Þ ¼ 0 for hsemen%x%htotal: (8)
Numerical methods
The partial differential equations are solved using the MATLAB (The Math-
works, Natick, MA) partial differential equation solver ‘‘pdepe’’ to obtain
concentration profiles of HIV in the semen and gel compartments over
time from the onset of semen-gel contact. These profiles are integratedTABLE 1 Variable and parameter deﬁnitions, with reference conditions
Variable Definition Reference condition
CHIV Concentration of HIV —
DHIV, semen Diffusion coefficient of HIV in semen 3.63  108 cm2/s
dHIV Diameter of HIV virion 125 nm
msemen Viscosity of semen 1 cP
T Temperature 37C
DHIV, gel Diffusion coefficient of HIV in microbicide gel 0.5 Dsemen
FHIV Partition coefficient between semen and gel layers 1
C0 Initial concentration of HIV in semen 5  104 virions/ml ¼ 8.3  1017 M
hsemen Thickness of semen layer 340 mm
hgel Thickness of microbicide gel layer 300 mm
htotal Total thickness of semen and microbicide gel layers, htotal ¼ hsemen þ hgel 640 mm
Mtissue Amount of HIV in tissue compartment —
Vsemen Volume of semen 3.4 ml
Vgel Volume of microbicide gel 3.0 ml
Avagina Surface area of vaginal epithelium 100 cm
2
f Fractional area coated by gel of given thickness 1
threshold Threshold number of virions in tissue compartment 1.7  104 virions
Values were input to the model unless otherwise specified.Biophysical Journal 97(9) 2379–2387
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coating thickness to determine the total amount of virus in the semen and
gel compartments. The time-dependent amount of HIV in the tissue
compartment, Mtissue(t), is calculated by a mass balance, subtracting the
amounts of virus in the semen and gel compartments from the initial amount
of virus in the semen. For a constant gel coating thickness, hgel,
MtissueðtÞ ¼ C0Vsemen  Avagina
2
4f
Zhgel þ hsemen
0
CHIV;coatedðx; tÞdx
þ ð1 fÞ
Zhsemen
0
CHIV;uncoatedðx; tÞdx
3
5:
(9)
Using the results for M(t), we find the times necessary for defined threshold
numbers of virions to migrate to the tissue compartment. These times,
tthreshold, are used as metrics to evaluate the effects of different model param-
eters, e.g., diffusion coefficients in semen and gel, layer thicknesses, and
fraction of surface coated by gel. The rationale for choosing tthreshold is
described below.
Model parameters
Ourmodel contains bothbiophysical parameters (e.g., diffusion coefficients in
semen and gel) and biological and human use parameters (e.g., gel and semen
volumes). Values from Table 1 are input to the model unless otherwise noted.
Diffusion coefﬁcients
The diffusion coefficient of HIV in semen (DHIV,semen) is estimated using the
Stokes-Einstein equation (29). HIV is taken as a sphere of diameter 125 nm
(30). Semen is treated as a Newtonian fluid with viscosity 1 cP. Then,
DHIV,semen¼ 3.6 108 cm2 s1. Human semen is a heterogeneous material,
and measurements of its viscosity have produced results typically within the
range 3–7 cP (31). This may be due in part to differences in the viscometric
methods employed. Our use of the viscosity 1 cP simulates waterlike semen
properties and thus provides the highest, and therefore most conservative,
value for DHIV,semen. That is, it leads to the lowest estimates of tthreshold.
There has been little work quantifying diffusion coefficients of HIV in
aqueous gels. Recent work indicates that HIV mobility is reduced in human
cervical mucus (32). We can also infer that gels have the potential to hinder
HIV diffusion from studies of nanoparticles in cervical mucus (33) and
studies of small molecules in microbicide gels (34). Further work is needed
to characterize likely reductions in diffusion coefficient of HIV in different
gel materials. To allow for a range of possible values of viral hindrance in
our model, the diffusion coefficient of HIV in vaginal gels (DHIV,gel) is
varied relative to the diffusion coefficient of HIV in semen (DHIV,semen):
DHIV,gel ¼ DHIV,semen, 0.5DHIV,semen, or 0.1DHIV,semen.
Partition coefﬁcient
We assume that the partition coefficient at the semen/gel interface (FHIV)
was 1. We expect this to be a reasonable approximation because vaginal
gel formulations, like semen, are hydrophilic with high water content. As
a result, the semen/gel interface likely becomes indistinct after some time
of contact. Furthermore, this provides a conservative estimate, maximizing
the number of virions that diffuse from the semen layer into the gel layer.
Gel and semen parameters
Volumes of microbicide gels used in clinical trials range from 2 to 5 ml
(35–38). Here, we use an intermediate volume of 3 ml. The average volume
of the human ejaculate (Vsemen) is 3.4 ml (31). If the volume of semen isBiophysical Journal 97(9) 2379–2387distributed relatively evenly over the area of the vagina, then an effective
semen layer thickness is represented by hsemen ¼ Vsemen=Avagina. The shape
and surface area of the vagina vary among individuals. Using vinyl polysi-
loxane casts, Pendergrass et al. found that the surface area of the human
vagina ranged from 65.73 to 107.07 cm2 (39). A comparable value was
found using MRI (40). Here, an intermediate value of 100 cm2 is used for
vaginal surface area (Avagina). This yields an effective value of hsemen ¼
340 mm.
HIV concentration
HIV viral load in semen varies with stage of infection, antiviral treatment,
and co-infection with genital tract infections (41). Risk of HIV transmission
is highest during acute HIV infection, during which the level of HIV RNA in
semen can reach 5 log10 to 6 log10 copies/ml (42,43). HIV RNA levels have
been found to be highest in men within 1 month of infection: in a recent
study quantifying HIV RNA levels in seminal plasma, median HIV RNA
level in nine acutely infected men was 5.0 log10 copies/ml (44). In our
model, we use this value of 105 copies/ml for HIV RNA in semen. There
are 2 copies of RNA per HIV virion, so this is equivalent to an initial concen-
tration of 5  104 virions/ml.
Threshold number of virions in tissue
compartment
The number of virions needed for HIV infection to occur is unknown, and
likely varies according to many biological factors related to infectiousness
of the virions and condition of their recipient (45). It is not possible to trans-
late HIV RNA copy number to measures of infectiousness (e.g., 50% tissue
culture infectious dose), because attempts to isolate HIV from semen are
typically unsuccessful. However, Klasse et al. (46) noted that the highest
risk of transmission from man to woman per coital act is 10%, which likely
reflects the scenario of highest infectiousness of the transmitter and highest
susceptibility of the recipient.
These current data are insufficient to link our model results to the clinical
outcome of infection. We use a conservative threshold of 1.7  104 virions
in computing values of tthreshold. This is one-tenth of the virions introduced in
an infectious ejaculate, assuming that semen volume is 3.4 ml and initial
concentration is 5  104 virions/ml. Considering that the highest risk of
transmission from man to woman per coital act is 10%, our chosen threshold
would approximately correspond to a 1% risk of infection at tthreshold. Micro-
bicides that increase time to threshold may allow more time for HIV virions
to be neutralized before virions diffuse to tissue surfaces. Using tthreshold
allows us to make comparisons among different scenarios. Although the
quantitative biological and clinical implications of our value for tthreshold
are uncertain, our model may easily be modified to accommodate new clin-
ical data on the number of virions needed to establish infection.
Application of diffusion model to in vivo vaginal
coating distributions
Experiments quantifying in vivo deployment of vaginal gels
Our group developed an optical probe for imaging deployment of vaginal
gels in women in vivo (22–24). The imaging technique outputs the spatial
distribution of gel coating thickness over vaginal epithelial surfaces, as illus-
trated in Fig. S1 in the Supporting Material. Gels are fluorescently labeled
with U.S.-Pharmacoepia-grade injectable fluorescein powder (typical
concentration 0.1% w/w). Coating thickness is linearly related to fluores-
cence for layers <1.5 mm thick. The resolution of the device is 15–25 mm
for gel thickness measurements.
Vaginal coating data were obtained for two commercial vaginal gels: K-Y
Jelly (Personal Products, Skillman, NJ), a hydroxyethylcellulose based
lubricant, termed gel K; and Replens (Lil’ Drug Store Products, Cedar
Rapids, IA) a Carbopol-based moisturizer, termed gel R. These were chosen
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properties, which give rise to different flow rates in fluid mechanical models
of vaginal coating (47–51). Imaging studies were performed in the clinic of
the Department of Obstetrics and Gynecology, Duke University Medical
Center, in a group of women of child-bearing age with no abnormalities
of anatomy or physiology of the reproductive tract. The group included
both parous and nulliparous women; measurements were performed
throughout the menstrual cycle except during menses.
Experiments were performed for two protocols for a woman’s activity after
gel application: without () and with (þ) simulated coitus. In both protocols,
a 3.5-ml bolus of gel was applied by a syringe-type applicator to the vaginal
fornix while the woman was in a supine posture. In the first protocol, the
woman remained supine for 20 min before imaging measurements
commenced. This simulated precoital conditions of gel use. In the second
protocol, the woman simulated coitus: after gel application, she assumed a
sitting position (1 min), a standing position (1 min), a sitting position
(1 min), and a supine position during which coitus was simulated by applying
30 strokes using an artificial phallus (~1 min). Imaging measurements were
performed 10 min after gel application. These protocols have been followed
in a number of prior imaging studies of vaginal gel distribution (52).
A total of eight experiments were performed in different women, with
duplicate experiments in each treatment combination (gel  activity). This
relatively small sample size is not sufficient to identify statistically signifi-
cant differences across each combination (gel  activity). However, it is
sufficient to exercise our new model of intravaginal HIV transport kinetics,
providing initial quantitative insights about HIV transport times in vivo.
Application of the model to in vivo vaginal coating data
Vaginal coating data are discretized (Fig. 3). Gel thicknesses are divided into
12 bins: 0 mm (areas in which no gel is detected), 0–50 mm, 50–100 mm,
100–150 mm, 150–200 mm, 200–250 mm, 250–300 mm, 300–350 mm,
350–400 mm, 400–450 mm, 450–500 mm, and >500 mm. An approximate
thickness value is input for hgel for each bin: 0 mm, 25 mm, 75 mm, 125 mm,
175 mm, 225 mm, 275 mm, 325 mm, 375 mm, 425 mm, 475 mm, and 525 mm,
respectively. Areas coated by gel layers of these thicknesses are normalized
to total area, to determine fractional area (fn) coated by a given thickness.
The total area of tissue input to the model is 100 cm2. The amount of virus
in the tissue compartment versus time is calculated using a modified version
of Eq. 9, into which multiple gel thicknesses and their respective fractional
coating areas are incorporated:
MtissueðtÞ¼C0Vsemen
Xm
n¼ 1
fn Avagina
Zhgel;n þ hsemen
0
CHIV;nðx; tÞdx:
(10)
Xm
n¼ 1
fn ¼ 1
Here, m is the number of bins, 12. The time to reach the threshold amount of
virus in tissue, tthreshold, is then determined.
RESULTS
Initial modeling for a surface entirely coated
at constant thickness
We initially applied the model to a surface fully coated by a
gel layer of constant thickness. This illustrated the primary
interaction between HIV diffusion coefficients and gel thick-
ness in governing HIV transport times. Fig. S2 shows the
amount of virus in the tissue compartment as a function oftime. Different combinations of gel thickness and HIV diffu-
sion coefficients are compared. Note that the presence of a
gel layer does not provide an absolute barrier to HIV diffu-
sion, i.e., the curves converge at the same maximum, where
all of the virions entered the tissue compartment. However,
the presence of a gel layer delays entry of HIV into the tissue
compartment. Increasing the gel layer thickness shifts the
curve to the right and increases time to threshold (Fig. S2 A).
Decreasing the diffusion coefficient for virus in gel shifts
the curve to the right and increases time to threshold
(Fig. S2 B).
Trade-offs between coating thickness
and the relative area of gel coating
To investigate trade-offs between the thickness of coating
(where it exists) and the area of tissue with coating, we
applied a schema in which the volume of gel was conserved
(Vgel ¼ 3 ml). Here, the gel coating thickness and fractional
area coated are inversely related:
hgel ¼ Vgel
fAvagina
: (11)
FIGURE 3 Schematic showing how model is applied to in vivo deploy-
ment data. Thickness data taken from in vivo experiments are discretized
into 12 bins, approximated by constant thickness. The fractional areas coated
by each of these approximated thicknesses were also derived from experi-
mental data. These, with the parameters defined in Table 1, were used to
calculate the time required to reach the threshold number of virions in the
tissue compartment, tthreshold.
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coated. Note that time to threshold increases as fractional
area coated increases, even though coating thickness
decreases (to conserve gel volume).
Fig. 4 also illustrates how delay of HIV diffusion to the
tissue surface can be attributed to the physical presence of
the gel layer, which distances the semen from the tissue.
This is represented by the scenario Dgel ¼ 1Dsemen, as
compared to the scenario in which there is no gel coating.
For gel layers a few hundred microns thick, such distancing
delays time to threshold by up to 3 h. When the gel layer
hinders viral diffusion (versus diffusion in semen), the time
to threshold is further increased. For Dgel ¼ 0.1Dsemen (i.e.,
the greatest degree of reduction in viral diffusion in gel
versus semen), there is a pronounced increase in slope of
this curve for f R 0.85. When Dgel ¼ 0.1Dsemen, the time
to threshold increases to as much as 22 h.
To further explore trade-offs between coating thickness
and fractional area coated, we generated a contour plot for
time to threshold, in which coating thickness, hgel, and frac-
tional area coated, f, are varied (Fig. 5). The curves in the
contour plot exhibit a notable bend at ~100 mm. This means
that, for deployment scenarios where coating thickness is
<100 mm, threshold time remains relatively constant for
a range of areas coated. For deployment scenarios where
coating thickness is >100 mm, fractional area coated is the
primary determinant of time to threshold. In the results
generated (not shown) for increased semen viscosity (and
therefore decreased Dsemen), the shapes of the curves were
qualitatively the same, but shifted to the right. That is, trends
were similar, but time to threshold increased.
We also generated a contour plot to explore conditions in
which viral hindrance significantly affects time to threshold
(Fig. S3). Recognizing from the trends shown in Fig. 5
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FIGURE 4 Trade-offs between gel layer thickness and area coated when
the volume of gel is conserved, such that hgel ¼ Vgel=fAvagina. As the frac-
tional area coated increases, time to threshold increases.Biophysical Journal 97(9) 2379–2387that the area coated is important in determining time to
threshold, we plotted time to threshold varying the level of
viral hindrance (Dgel/Dsemen) and fractional area coated for
a 300-mm coating layer (Fig. S3). We find that for f R
0.80, the level of viral hindrance contributes to determining
time to threshold. For f R 0.95, increasing viral hindrance
rapidly increases time to threshold. These results suggest
that a significant portion of the tissue must be coated for
levels of viral hindrance to contribute to the barrier function
of a microbicide gel.
Inputting in vivo vaginal coating data to model
showed differences between application
protocols
To examine how gels would act to hinder viral diffusion
in vivo, we input experimental deployment data to the math-
ematical model (Fig. 3). Deployment data for a small sample
of in vivo data for vaginal coating thickness distributions
were selected. These provided a range of fractional areas
with detectable coating, and of the distributions of thick-
nesses within that coating (Table S1). The deployment data
were summarized as discretized thicknesses and correspond-
ing fractional areas coated. These experimental inputs and
other model parameters were used to calculate the time to
threshold for different vaginal gels, application protocols,
and levels of viral hindrance by the gel.
Fig. 6 shows the resulting model outputs of tthreshold. There
was little difference in tthreshold between gels. Gel application
protocol (with or without simulated coitus) had a more
significant effect on time to threshold. Simulated coitus
increased the fractional area coated from ~60–87% to nearly
100% (Table S1). Shearing forces of simulated coitus spread
the gels over tissue surfaces, and the calculated time to
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FIGURE 5 Contour plot showing values of threshold time for different
gel thicknesses and fractional areas coated. Note that fractional area coated
is the more important factor for all but the thinnest gel layers.
2385threshold increased as a result. For deployment data from
experiments without simulated coitus, there was little differ-
ence in tthreshold for different reductions in viral diffusion
coefficient; time to threshold was <1.5 h, regardless of the
reduction. In contrast, for experiments with simulated coitus,
a higher level of viral hindrance (Dgel ¼ 0.1 Dsemen) added
hours to tthreshold compared to cases in which diffusion was
not hindered (Dgel ¼ 1Dsemen). For gels with Dgel ¼
0.1Dsemen, calculated time to threshold was nearly 8 h. The
Supporting Material (Fig. S4) describes the work we per-
formed to identify a summary measure of gel thickness
distribution, the harmonic mean, that is useful for estimating
viral transport times.
DISCUSSION
We have developed a mathematical model for in vivo HIV
transport in the presence of a microbicide gel. The model
analyzes diffusion of HIV virions from semen to tissue in the
presence of a biologically realistic vaginal coating,with incom-
plete coverage and nonuniform thickness. Total HIV transport
to tissue occurs over coated and uncoated regions. To compare
different scenarios, we use the metric of time required for a
threshold number of virions to enter the tissue compartment.
Results indicate that comprehensive coating by microbi-
cide gels is crucial to increasing time to threshold. For
example, for a conserved volume of gel, we sought to deter-
mine whether it is more important to coat a greater area with
thinner layers or a smaller area with thicker layers. We found
that time to threshold increases with increasing fractional
area coated, even though the thickness of gel layers
decreases. Analyzing different deployment scenarios, we
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FIGURE 6 Resulting threshold times for application of the mathematical
model to experimental data obtained from deployment of vaginal gels in
women. The numbers ‘‘1’’ and ‘‘2’’ represent data from two independent
experiments for each gel/protocol. K, KY jelly; R, Replens; þ, with simu-
lated coitus; , without simulated coitus. Three levels of viral hindrance
were input (Dgel/Dsemen ¼ 0.1, 0.5, and 1).
HIV Transport in Topical Microbicidesalso found that there is a cutoff in effective coating thickness:
below ~100 mm, time to threshold was brief, regardless of the
fractional area coated. However, for thicknesses >~100 mm,
increasing fractional area coated increased the time to
threshold. When coating was incomplete, HIV transport to
the epithelium occurred primarily over surfaces in which
there was direct contact between semen and uncoated tissue.
When fractional area was >~80%, both gel thickness and
level of viral hindrance (i.e., reduced diffusion coefficient)
contributed to increasing the time to threshold. Taken
together, these results suggest the importance of comprehen-
sive coating in determining the ability of a microbicide gel to
function as a barrier to HIV. Microbicide formulators should
consider the importance of deployment as they design prod-
ucts that function by preventing or delaying the contact
between HIV virions and vulnerable tissue.
The model was also used to provide an objective context
for interpreting in vivo data for the extent and thickness of
vaginal coating. Our human imaging study was relatively
small (n ¼ 8), but it provided insights about differences in
vaginal coating, and about how to consolidate coating data.
The protocol involving simulated coitus (þ) produced
a larger coated surface area than that in which women re-
mained supine after gel application (), and the calculated
HIV transport times were longer as a result.
In the state of development presented here, our model does
have limitations. Some input parameters were approxima-
tions. For example, to our knowledge, the diffusion coeffi-
cients of HIV in semen and microbicide gels have not yet
been measured. We expect HIV diffusion in a typical viscous
vaginal gel to be slower than it is in semen (e.g., due to
increased viscous drag, physical obstruction, and electro-
static interactions with polymers). We used the Stokes-Ein-
stein relation to conservatively approximate the diffusion
coefficient of HIV in semen, and computations were subse-
quently performed while varying the ratio Dgel/Dsemen.
However, the motion of particles through polymer solutions
can be complicated, especially when the particle is compa-
rable in size to the mesh formed by polymer chains. More
complex mathematical models for estimating the diffusion
coefficients of particles in polymer solutions account for
mechanisms such as hydrodynamic drag on particles and
physical obstruction by polymer chains (53). Experimental
methods are being developed for determining HIV diffusion
coefficients in gels (34), semen, and cervical mucus (32), and
results of these studies can be readily incorporated into the
computational framework presented here. Furthermore, we
assumed that diffusion coefficients of virions in semen and
gel were constant over time, thereby neglecting possible
changes due to dilution of gel with semen and vaginal fluid.
In our model, we also assumed that HIV infection occurs
via cell-free virus. However, cell-associated virus may play a
role in HIV transmission (54), e.g., via infected immune
cells such as lymphocytes, monocytes, and/or macrophages.
Such cells are much larger than free virions, with diametersBiophysical Journal 97(9) 2379–2387
2386 Lai et al.of the order of 10–20 mm, whereas the diameter of an HIV
virion is ~125 nm. Thus, we would expect cell transport via
simple diffusion to be much slower than that for free HIV
virions. However, unlike free virions, these cells are motile.
The analogous diffusion coefficient, or motility coefficient,
of cells in semen or gel could be closer to that of free virus.
Saltzman et al. found motility coefficients of monocytes in
synthetic polymer gels to be ~109–1010 cm2 s1 (55).
Although further studies will continue to elucidate the roles
of cell-associated and cell-free virus, we note that cell-free
transmission is consistent with animal models used currently
to evaluate microbicide products.
Our model assumed that HIV transport is a result of simple
diffusion, and did not consider the possible role of convective
transport. Coital activity (viz. shearing by the penis) likely
causes movements of fluids within the vagina (including
gels) that would give rise to such transport. The work here
is thus more relevant to HIV transport after coitus. Moreover,
it is unclear whether convective processes would affect trans-
port of HIV at mucosal surfaces. There is, at times, likely
some convection of transudate fromvaginal tissues, and clear-
ance of fluids out of the vagina. Clearance of virus due to these
mechanismswould likely reduce the number of virions reach-
ing the tissue surface, and thus, we believe that our model
provides an estimate of the upper bound of the number of
virions that could reach tissue surfaces, i.e., a conservative
lower-bound estimate of the time to threshold.
To evaluate different scenarios, we used the time needed
for a threshold number of virions to enter the tissue compart-
ment. There is currently a lack of experimental data needed
to relate this value to measures of clinical outcome. In the
future, it may be helpful to incorporate this approach, which
addresses the spatiotemporal distributions of virions, with
stochastic theory, which incorporates data from clinical
trials. This could provide increased understanding of the
extent to which factors under developer control (e.g., phar-
maceutical agent potency, concentration, and delivery
system) determine microbicide product efficacy.
Finally, this study did not account for HIV neutralization
by pharmaceutical agents. We made this choice because
there are currently >10 microbicides in clinical trials and
several agents in the pipeline (56), with several different
mechanisms of action and dosage forms among them. This
study focused on exploring how gel deployment and trans-
port properties could affect the barrier functions of a micro-
bicide gel. A logical follow-up to the modeling here will be
to incorporate the simultaneous transport of specific anti-
HIV pharmaceutical agents for a specific microbicide
product.
A number of transport processes interact in the func-
tioning of vaginal microbicide gels, including movement
of active ingredients and virions. Understanding these
processes will contribute to a fundamental understanding
of the functioning of microbicide gels, and to the design of
gels with improved performance. To date, there have beenBiophysical Journal 97(9) 2379–2387few attempts to develop mathematical models for topical
microbicides. This is probably due to the fact that sexual
transmission of HIV is complex and poorly understood.
Furthermore, topical microbicides often deliver drugs locally
rather than systemically, so the analyses used in traditional
pharmacokinetic modeling, where entire organs are treated
as single compartments, are less relevant. There is also
a lack of experimental pharmacokinetic data for topical
microbicides from humans or animal models: biopsies of
vaginal tissue are invasive, and there can be high variability
in collection and analysis of cervicovaginal lavages and
cytobrush specimens. Without these pharmacokinetic data,
mathematical models cannot be validated. Additional collab-
orations among researchers using experimental and mathe-
matical approaches are needed. Ultimately, mathematical
models for topical microbicides could serve as valuable tools
in understanding mucosal HIV transmission, development of
new prevention technologies, and design of clinical trials.
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